Liver Diseases Center

INSTITUTE
University Hospitals Digestive Health Institute

MEDICAL DIRECTOR
Pierre M. Gholam, MD
Pierre.Gholam@UHhospitals.org

SURGICAL DIRECTOR

KEY CONTACTS
Anthony Post, MD; S. Martin Cohen, MD

APPOINTMENT LINE
For hospital transfers, please call 216-844-1111.

Coordinators and Contact Information
• For transplant referrals and intake, please call Pamela Diamond at 216-844-3689.
• For medical referrals to the Liver Diseases Center, please call Rhonda Wynn at 216-844-5387.
• For referrals for surgical treatment at the Liver Diseases Center, please call Linda Little at 216-844-0489, option 2.
• For hospital transfers, please call 216-844-1111.

Conditions Treated

• Chronic hepatitis C infection
• Non-alcoholic steatohepatitis (NASH)
• Fatty liver disease
• End-stage liver disease requiring liver transplantation
• Cirrhosis of the liver
• Hepatocellular carcinoma (primary liver cancer)
• Cholangiocarcinoma (bile duct cancer)
• Benign liver tumors (hemangioma, adenoma, FNH)

Therapies

• Liver transplantation
• Antiviral therapy for HCV infection
• Surgical resection of malignant and benign liver tumors
• Radiofrequency ablation for hepatocellular carcinoma
• Transarterial chemoembolization (TACE) for hepatocellular carcinoma
• Transarterial radioembolization (TARE/Y90) for hepatocellular carcinoma
• Systemic chemotherapy for hepatocellular carcinoma

Liver Diseases Center

• Chronic hepatitis B infection
• Alcoholic liver disease
• Primary biliary cholangitis
• Primary sclerosing cholangitis
• Hereditary hemochromatosis
• Vascular liver disease (portal vein thrombosis, Budd-Chiari syndrome)
• Alpha one antitrypsin deficiency
• Wilson disease
• Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma
• Antiviral therapy for hepatitis B
• Clinical trials for reversal of liver fibrosis/cirrhosis, fatty liver disease, hepatitis C and liver cancer
• Treatment of cholestatic liver disease
• Genetic testing and counseling for inherited disorders of the liver
• Phlebotomy and follow-up of hereditary hemochromatosis

Distinguishing Features

• Expedited evaluation of candidacy for liver transplantation for the patients who are most ill
• Multidisciplinary hepatobiliary tumor board, with broad participation from expert surgeons, hepatologists, medical oncologists, interventional radiologists, pathologists, radiation oncologists and palliative care specialists
• Nationally and internationally published quality and outcomes data
• Access to state-of-the-art treatment, including early-phase clinical trials for patients with liver cancer
• One of the largest hepatitis C treatment clinics in the U.S., with more than 1,000 patients treated and cured in the last two years
• Access to state-of-the-art clinical trials for all the latest investigational treatments for fatty liver disease
• Access to first-ever clinical trials for reversal of cirrhosis and liver fibrosis
• NIH-funded clinical and research program in alcoholic liver disease